Welcome to our dedicated page for Pharvaris N.V. SEC filings (Ticker: PHVS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Pharvaris N.V. filings document foreign private issuer disclosures for a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists. Form 6-K reports furnish financial results, business updates, investor presentations, clinical-study updates, annual general meeting voting results and materials incorporated by reference into Form F-3 and Form S-8 registration statements.
The filing record also covers capital-structure activity involving ordinary shares and pre-funded warrants, registration rights agreements, underwriting documents, share-based compensation and governance matters. These disclosures frame Pharvaris' development-stage operating expenses, financing activity, shareholder approvals and formal reporting obligations as a Nasdaq-listed foreign private issuer.
Morgan Stanley Smith Barney LLC Executive Financial Services filed a Form 144 notice related to proposed sales of Common Stock of PHVS. The excerpt lists 4,667 shares described as Restricted Stock with a 04/11/2025 date and 4,137 shares from a Stock Option Exercise with a 05/15/2026 date.
Pharvaris N.V. Chief Medical Officer Lu Peng reported tax-withholding dispositions of 226 shares of Common Stock connected to restricted stock unit vesting on May 11 and May 12, 2026. On those dates, 109 shares were withheld at $30.09 per share and 117 shares at $29.95 per share to satisfy tax obligations, leaving him with 65,857 shares held directly.
Pharvaris N.V. reported first-quarter 2026 results showing continued investment in late-stage hereditary and acquired angioedema programs and a sizeable cash buffer. Cash and cash equivalents were €247 million as of March 31, 2026, supplemented by a subsequent $132 million underwritten equity offering, which the company says extends its cash runway into 2028.
For the quarter, Pharvaris recorded a net loss of €39.2 million, improved from €46.3 million a year earlier, as finance income offset slightly higher operating expenses. Research and development expenses were €30.2 million, largely driven by late-stage deucrictibant trials, while general and administrative costs rose to €14.1 million as the company prepares for potential commercialization.
Topline data from CHAPTER-3, the pivotal Phase 3 study of deucrictibant XR for prophylaxis of hereditary angioedema attacks, are expected in the third quarter of 2026, and submission of a New Drug Application for deucrictibant IR for on-demand treatment remains planned for the first half of 2026. Enrollment continues in CHAPTER-4 and CREAATE, supporting a potential end-to-end oral treatment portfolio.
Pharvaris N.V. is offering 3,874,664 ordinary shares at an offering price of $29.68 per share in a registered primary offering. The offering nets $108,100,026 to the company before expenses; the underwriters have a 30‑day option to purchase an additional 581,199 shares. Proceeds are earmarked primarily for research and development, U.S. commercial expansion and general corporate purposes. The prospectus supplement discloses a cash balance of approximately €247.0 million as of March 31, 2026 and management’s estimate that, assuming planned uses and full option exercise, combined funds are expected to fund operations into the first half of 2028, subject to the stated assumptions.
Pharvaris N.V. Chief Medical Officer Lu Peng reported an exercise-and-sale transaction in company stock. On May 1, 2026, Peng exercised stock options to acquire 14,166 shares of common stock at an exercise price of $2.59 per share, then sold the same number of shares in open-market trades under a pre-arranged Rule 10b5-1 trading plan. The sales, executed as a cashless exercise, had weighted average prices around $30–$31 per share. Following these transactions, Peng directly holds 66,083 shares of Pharvaris common stock.
Pharvaris N.V. director Johannes Schikan reported open-market sales of a total of 32,900 shares of common stock. The sales occurred on April 29–30 at weighted average prices of $30.07, $30.30, and $31.03 per share under a pre-set Rule 10b5-1 trading plan. After these transactions, he directly holds 355,167 shares, indicating the sales represent a relatively small portion of his overall position and appear to be routine, pre-planned disposals rather than discretionary trades.
Pharvaris N.V. executive Anne Lesage, Chief Early Development, reported a mix of stock option exercises and open-market sales in Pharvaris common stock. Over two days, she exercised 25,400 shares through stock options at exercise prices of $8.05 and $2.59 per share and sold 48,300 shares in open-market transactions under a pre-arranged Rule 10b5-1 trading plan.
Following these transactions, the filing shows Lesage holding 56,450 Pharvaris common shares directly and 133,969 shares indirectly through GrayMatters Consulting B.V., an entity she controls. Remaining stock options include 82,000 options with an $8.05 exercise price and 9,072 options with a $2.59 exercise price.
Lu Peng, Chief Medical Officer of Pharvaris N.V., reported an exercise-and-sale sequence under a Rule 10b5-1 trading plan. Peng exercised options to acquire 18,733 shares of common stock at $2.59 per share and sold the same number of shares in open-market transactions at weighted average prices around $30 on April 29–30, 2026.
Following these transactions, Peng directly holds 66,083 shares of Pharvaris common stock and 219,474 stock options from the referenced grant, which remains outstanding until February 3, 2030.
Pharvaris N.V. director Johannes Schikan reported open-market sales of 7,100 shares of Common Stock in two transactions. He sold 7,000 shares on April 22, 2026 at $30.0541 per share and 100 shares on April 23, 2026 at $30.03 per share, under a pre-planned Rule 10b5-1 trading plan. Following these sales, he directly holds 388,067 Pharvaris shares.